Also, treatment with Sild-Met-Leu increased Sirt1 protein expression in mouse AML-12 hepatocytes and reduced lipogenic protein expression of SREBP1, SCD1, and FAS similar to our observations in HepG2 cells (data not shown). Here, FAS is linked to acute myeloid leukemia.